American Heart Journal
Volume 145, Issue 5 , Pages 768-778, May 2003

Brugada syndrome and “Brugada sign”: Clinical spectrum with a guide for the clinician

  • Laszlo Littmann, MD

      Affiliations

    • Department of Internal Medicine, Carolinas Medical Center, Charlotte, NC, USA
    • Corresponding Author InformationReprint requests: Laszlo Littmann, MD, Department of Internal Medicine, Carolinas Medical Center, PO Box 32861, Charlotte, NC 28232, USA.
  • ,
  • Michael H Monroe, MD

      Affiliations

    • Department of Internal Medicine, Carolinas Medical Center, Charlotte, NC, USA
  • ,
  • William P Kerns II, MD

      Affiliations

    • Department of Emergency Medicine, Carolinas Medical Center, Charlotte, NC, USA
  • ,
  • Robert H Svenson, MD

      Affiliations

    • Department of Sanger Clinic, P.A., Charlotte, NC, USA
  • ,
  • John J Gallagher, MD

      Affiliations

    • Department of Sanger Clinic, P.A., Charlotte, NC, USA

Abstract 

Background

Patients with the manifest Brugada syndrome have an inordinate risk of sudden death and are candidates for implantation of a defibrillator. The Brugada type electrocardiogram (ECG) abnormality (the “Brugada sign”), however, is known to be associated with a wide range of conditions, many of which may not pose such a threat. Clinicians need guidance in choosing a rational approach for the evaluation and treatment of patients with a finding of the Brugada sign.

Methods

A systematic literature search was performed to identify publications on the Brugada syndrome and the Brugada-type ECG abnormality, with special emphasis on analyzing outcomes data. In addition, the ECG database of our institution was reviewed for tracings consistent with the Brugada sign, and, when possible, clinical correlations were made.

Results

Patients with the Brugada sign and a family history of sudden death or a personal history of syncope are at a high risk of sudden death and therefore should be strongly considered for implantation of a defibrillator. In patients who are hospitalized and critically ill, the Brugada sign is frequently the result of severe hyperkalemia, drug toxicity, or right ventricular injury. In most individuals with no symptoms and without a family history of sudden death, the Brugada sign is likely a normal variant.

Conclusions

Most patients with the Brugada sign can be risk-stratified with simple clinical tools. Specific testing for the Brugada syndrome should be reserved for questionable cases and for the research setting. A provisional diagnostic-therapeutic algorithm is offered as a means of assisting the clinician in the evaluation and treatment of patients with the Brugada sign.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0002-8703(03)00081-4

doi:10.1016/S0002-8703(03)00081-4

American Heart Journal
Volume 145, Issue 5 , Pages 768-778, May 2003